The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines.
作者信息
Ruggeri Kai, Maguire Áine, Cook Gordon
机构信息
Department of Psychology, University of Cambridge, Cambridge, England.
Leeds University & Leeds Teaching Hospital, St James Hospital, Leeds, England.
出版信息
JAMA Oncol. 2016 Nov 1;2(11):1405-1406. doi: 10.1001/jamaoncol.2016.1782.
PMID:27355621
Abstract
摘要
相似文献
1
The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines.
JAMA Oncol. 2016 Nov 1;2(11):1405-1406. doi: 10.1001/jamaoncol.2016.1782.
2
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Clin Adv Hematol Oncol. 2019 May;17 Suppl 9(5):2-8.
3
A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Clin Adv Hematol Oncol. 2019 May;17 Suppl 9(5):1-19.
4
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18.
5
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Cancer. 2013 Jan 15;119(2):339-47. doi: 10.1002/cncr.27745. Epub 2012 Jul 18.
6
NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments.
Lancet Oncol. 2016 Mar;17(3):279-80. doi: 10.1016/S1470-2045(16)00061-9. Epub 2016 Jan 27.
7
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1.
Leukemia. 2018 Sep;32(9):2032-2036. doi: 10.1038/s41375-018-0091-3. Epub 2018 Mar 12.
8
Panobinostat for the treatment of multiple myeloma.
Lancet Oncol. 2014 Oct;15(11):1178-9. doi: 10.1016/S1470-2045(14)70443-7. Epub 2014 Sep 18.
9
Daratumumab combination prolongs myeloma survival.
Lancet Oncol. 2016 Oct;17(10):e422. doi: 10.1016/S1470-2045(16)30439-9. Epub 2016 Sep 3.
10
A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis.
Leuk Lymphoma. 2019 Jan;60(1):151-162. doi: 10.1080/10428194.2018.1466392. Epub 2018 Nov 8.
Zotero 插件